Company news

Mind Cure Health Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Mind Cure Health Inc. (to be renamed LNG energy group corp.) announces completion of business combination transaction

August 15, 2023

Mind Cure announces closing of LNG energy's subscription receipt financing

August 5, 2023

Mind Cure announces LNG energy Group credit agreement in the amount of U.S. $70 million to acquire lewis energy colombia, inc.

July 27, 2023

Mind Cure Health Inc. announces closing of the first tranche of LNG energy group's subscription receipt financing

June 9, 2023

Mind Cure and LNG energy group provide update on previously announced business combination transaction

June 8, 2023

Mind Cure closes previously announced private placement

May 11, 2023

CSE Bulletin: Halted for Fundamental Change - Mind Cure Health Inc. (MCUR, MCUR.WT)

May 9, 2023

Mind Cure and LNG energy group enter into arrangement agreement with respect to previously announced business combination transaction

May 5, 2023

MINDCURE Announces Financial Results for the Third Quarter of Fiscal 2023

April 20, 2023

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2023

January 25, 2023

Mind Cure enters into binding letter of intent with LNG energy group

November 18, 2022

Mind Cure enters into binding letter of intent with LNG energy group

November 18, 2022

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2023

October 26, 2022

MINDCURE Announces Financial Results for Fiscal 2022

September 13, 2022

MINDCURE Announces Financial Results for the Third Quarter of Fiscal 2022

April 26, 2022

MINDCURE Provides Update on Strategic Review

March 16, 2022

MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program

March 2, 2022

MINDCURE Announces Strategic Review

February 10, 2022

MINDCURE Hires Dr. Clare Purvis from Headspace to the position of Chief Product Officer to Advance Mental Health Digital Therapeutics Platform

February 3, 2022

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022

January 25, 2022

MINDCURE to Participate in the H.C. Wainwright Bioconnect Conference in January 2022

January 6, 2022

MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022

December 16, 2021

MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer

December 14, 2021

MINDCURE to Participate in Upcoming Conferences in December 2021

December 2, 2021

MINDCURE Provides Update on Studies and Clinical Trials

November 4, 2021

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE's Digital Therapeutics Platform

October 28, 2021

MINDCURE Announces Participation at Upcoming Events in November 2021

October 27, 2021

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022

October 26, 2021

MINDCURE to Webcast Live at the KCSA Psychedelics Virtual Investor Conference on October 13, 2021

October 7, 2021

MINDCURE Announces Commencement of Trading on the OTCQX Best Market

September 30, 2021

MINDCURE Announces Financial Results for Fiscal 2021

August 31, 2021

MINDCURE Welcomes Dr. Ken Weingardt, Digital Therapy Visionary, as a Senior Clinical Technology Advisor to its Psychedelic Digital Therapeutics Team

August 10, 2021

MINDCURE Appoints Jerry White, Award-Winning Humanitarian Activist Who Shares in the 1997 Nobel Peace Prize, as Company Advisor

August 4, 2021

MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

July 27, 2021

MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound

July 13, 2021

MINDCURE Adopts Advance Notice Policy

July 12, 2021

Maxim Group Initiates Coverage of Mind Cure Health

June 30, 2021

MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression

June 17, 2021

MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

June 3, 2021

Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer

May 20, 2021

MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children's Hospital, as Company Advisor

May 19, 2021

MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM's Market Launch, Delivering Mental Wealth

April 29, 2021

MINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork Program and Develop Custom Breathwork for Psychedelic-Assisted Psychotherapies within iSTRYM

April 27, 2021

MINDCURE Announces Experienced Finance Executive Michael Wolfe as CFO and appoints Larissa Chaikowsky to its Board of Directors

April 22, 2021

MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions

April 21, 2021

MINDCURE Announces The Addition of Daniel Herrera, A Pharmaceutical Industry Executive With Specific Experience in Medical Psychoactive Segment

April 14, 2021

MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company's Psychedelic Digital Therapeutics Technology Platform

April 13, 2021

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

April 8, 2021

MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients

March 31, 2021

March Psychedelic Capital Investigates Ethical IP and Financial Instruments

March 30, 2021

Older news releases →